Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$47.6K-93.78%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sabrina Martucci Johnson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Beta
- 1.15
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -13.60
Financials
Revenue
$47.6K-93.8%Net Income
$-3.16MEBITDA
$-3.16MFree Cash Flow
$-7.05MEPS (diluted)
$-0.18Shares Outstanding (diluted)
17.42M+528.7%Operating Expenses
$2.96MCash & Debt
$11.53MRevenue by Segment (annual)
$12.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.03M | $-13.40M | $-1.20 |
| 2024 | $9.8K | $-4.05M | $-0.48 |
| 2023 | $2.81M | $-30.16M | $-4.15 |
| 2022 | $10.00M | $-30.95M | $-4.39 |
| 2021 | $0.00 | $-38.70M | $-7.52 |
| 2020 | $0.00 | $-27.40M | $-10.93 |
| 2019 | $0.00 | $-14.26M | $-10.99 |
| 2018 | $0.00 | $-16.74M | $-30.16 |
| 2017 | $0.00 | $-11.50M | $-3.56 |
| 2016 | $766.0K | $-39.30M | $-30.02 |
| 2015 | $0.00 | $-39.59M | $-15.57 |
| 2014 | $80.0K | $-23.34M | $-192.00 |
| 2013 | $6.0K | $-17.14M | $-108.19 |
| 2012 | $625.0K | $-22.10M | $-280.83 |
Valuation
DAREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (20)
- Newsseekingalpha.com·5d ago·Positive
Daré Bioscience, Inc. (DARE) Q3 2026 Earnings Call Transcript Daré Bioscience, Inc. (DARE) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·6d ago·Negative
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.28 per share a year ago.
View source ↗ - Newsglobenewswire.com·6d ago·Positive
Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington, D.C.
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding Additional funding represents the second-to-last anticipated payment under the up to approximately $10.7 million grant agreement supporting preclinical development of a novel non-hormonal intravaginal contraceptive Additional funding represents the second-to-last anticipated payment under the up to approximately $10.7 million grant agreement supporting preclinical development of a novel non-hormonal intravaginal contrace
View source ↗ - Newsglobenewswire.com·12d ago·Negative
…026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026 SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will host a conference call and webcast at 4:30 PM Eastern Time on Monday, November 16, 2026, to review its financial results for the quarter ended September 3…
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Daré Bioscience Releases Next Episode in “CEO Corner” Video Series Sabrina Martucci Johnson, Founder, President and CEO, discusses numerous potential value drivers expected to power the Company's next phase of growth and commercial success
View source ↗ - Newsglobenewswire.com·18d ago·Negative
Daré Bioscience to Present at Stifel's 2026 Healthcare Conference SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience, is scheduled to present at Stifel's 2026 Healthcare Conference happening November 10 – 12, 20…
View source ↗ - Newsglobenewswire.com·23d ago·Neutral
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
Daré Bioscience Addresses New National Focus on Women's Health in Virtual Investor “What This Means” Discussion Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience's growing commercial portfolio and clinical pipeline position the Company to address critical unmet needs in women's health
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic priorities
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection
View source ↗ - Newsglobenewswire.com·83d ago·Positive
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series Video webcast now available here
View source ↗ - Newsseekingalpha.com·88d ago·Positive
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
View source ↗ - Newsglobenewswire.com·88d ago·Positive
…l systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA's 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**
View source ↗ - Newsglobenewswire.com·89d ago·Neutral
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value over the next 12–18 months Access the segment here
View source ↗ - Newsglobenewswire.com·96d ago·Neutral
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation
View source ↗ - Newsseekingalpha.com·100d ago·Positive
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·101d ago·Neutral
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.45 per share a year ago.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript
View source ↗
Earnings
Thu, Mar 25(in 4 months)
Consensus estimate $-0.20 per share
Typical surprise +25.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.18 vs $-0.13miss
- Thu, Aug 13$-0.20 vs $-0.30beat
- Thu, May 14$-0.20 vs $-0.33beat
- Thu, Mar 26$-0.02 vs $-0.24beat
- Thu, Nov 13$-0.28 vs $-0.33beat
- Thu, Aug 14$-0.45 vs $-0.55beat
Estimates and results for DARE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DARE officers and directors.
- Bought
- $500k
- Sold
- $382
1 trade
1 trade
- Rastetter William Hsold
- Hawley Rogerbought
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DARE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
